Cure Genetics develops cell and gene therapies utilizing AIMS CAR-NKT and VELPTM AAV platforms to target solid tumors and genetic diseases. The company addresses the need for effective treatments in oncology and complex genetic disorders through its differentiated therapeutic pipeline and global collaborations.
Funding
$9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing treatments for solid tumors and genetic diseases often lack efficacy, highlighting the need for innovative therapeutic approaches. Current cell and gene therapy methods face challenges in effectively targeting solid tumors, modulating the tumor microenvironment, and achieving sustained therapeutic effects. Furthermore, developing safe and efficient delivery methods for gene therapies, particularly for targeting specific organs, remains a significant hurdle.
Solution
Cure Genetics is developing cell and gene therapies utilizing two core technology platforms: AIMS CAR-NKT and VELPTM AAV. The AIMS CAR-NKT platform enhances solid tumor infiltration, modulates the tumor microenvironment, and extends sustained expansion, demonstrating a good safety profile in clinical studies targeting clear cell renal carcinoma. The VELPTM AAV platform focuses on developing novel adeno-associated viral (AAV) vectors for next-generation gene therapy, utilizing a diverse library and efficient in vivo AAV screening. By combining these platforms, Cure Genetics aims to provide effective treatment measures for patients with unmet medical needs in oncology and genetic diseases.
Target Audience
The primary target audience includes patients with solid tumors and genetic diseases who have unmet medical needs, as well as pharmaceutical companies seeking innovative cell and gene therapy technologies for licensing and collaboration.
Features
- AIMS CAR-NKT platform for enhanced solid tumor infiltration and modulation of the tumor microenvironment.
- VELPTM AAV platform for developing novel AAV vectors with improved safety and efficiency.
- Clinical-stage CAR-NKT product (CGC729) demonstrating a good safety profile and anti-tumor activity in patients with renal cell carcinoma (RCC).
- Collaboration with Boehringer Ingelheim (BI) to develop novel AAV vectors for liver-targeted gene therapy.
- Focus on autologous/allogeneic/in vivo CAR-NKT pipelines.
- VELPTM platform applications targeting the nervous system, heart, and kidneys.